Author: Zacks Small Cap Research

1234566640 / 658 POSTS
By Ian Gilson, PhD, CFANASDAQ:EAST READ THE FULL EAST RESEARCH REPORT The third quarter results were announced today. Net sales were $4.43 million as compared to our $4.45 million estimate. Since Eastside Distilling (NASDAQ:EAST) is no longer conside ...
By Brian Marckx, CFANASDAQ:EYEG READ THE FULL EYEG RESEARCH REPORT OBG-PRK: Pivotal Data Upcoming, 2020 Launch Feasible OBG-PE: Pre-Pivotal Study Moving Quick, Pivotal in 2020? We continue to be encouraged by the recent rapid and consistent progress ...
By Lisa ThompsonNASDAQ:TSEM READ THE FULL TSEM RESEARCH REPORT Q3 came in right at the midpoint of guidance and Q4 looks to be almost identical with Q3. As predicted, margins increased sequentially as revenues grew. Business and profits should reboun ...
By David Bautz, PhDNASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Two Phase 3 Data Readouts in 2020 Soligenix, Inc. (NASDAQ:SNGX) is a late-stage clinical biopharmaceutical company developing treatments in oncology, GI disorders, and ...
By Steven Ralston, CFATSX:WML.V | OTC:WMLLF READ THE FULL WML.V RESEARCH REPORT Wealth Minerals (TSX:WML.V) (OTC:WMLLF) is a junior mineral exploration company that is well-positioned to benefit from its portfolio of prospective lithium projects in t ...
By Ian Gilson, PhD, CFANASDAQ:SNES READ THE FULL SNES RESEARCH REPORT On Nov. 12, 2019, SenesTech (NASDAQ:SNES) reported its third quarter results. In general the numbers were in line with our estimates with revenue of $0.04 million (Est. $0.04 milli ...
By David Bautz, PhDNASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Business Update R&D Meeting Highlights Pipeline of Addiction and Drug Overdose Treatments On October 17, 2019, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) held a research and develo ...
By John Vandermosten, CFANASDAQ:PHIO Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported third quarter 2019 results and filed its Form 10-Q on November 12, 2019. Since the beginning of the year, the company has announced a several new collaborations wi ...
By Ian Gilson, PhD, CFANASDAQ:MBII READ THE FULL MBII RESEARCH REPORT Marrone Bio's (NASDAQ:MBII) third quarter revenue was in line with our estimate, $6.97 million actual (including some into the hemp market) versus our $6.80 million estimate. Gross ...
By David Bautz, PhDTSX:MDNA.TO READ THE FULL MDNA.TO RESEARCH REPORT Business Update MDNA55 Update Medicenna Therapeutics, Inc. (TSX:MDNA.TO) is developing MDNA55 for the treatment of recurrent glioblastoma (rGBM). The company is currently conducting ...
1234566640 / 658 POSTS